Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD

Pulmonary Pharmacology and Therapeutics

Volumn 27, Issue 1, 2014, Pages 90-95

  Salvi, Sundeep ^a   Brashier, Bill ^a   Gothi, Dipti ^b   Karkhanis, Vinaya ^b   Madas, Sapna ^a   Gogtay, Jaideep ^c   Joshi, Jyotsna ^b  

^a Chest Research Foundation   (India)

^b BYL Nair Hospital   (India)

^c CIPLA LTD   (India)

Author keywords

COPD; Formoterol; Tiotropium

Indexed keywords

FORMOTEROL; TIOTROPIUM BROMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; MALE; MEASUREMENT; METERED DOSE INHALER; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

COPD; FORMOTEROL; TIOTROPIUM;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892432502     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.05.010     Document Type: Article

References (25)

1. Global Initiative for Chronic Obstructive Lung disease Global strategy for diagnosis, management and prevention of COPD 2006, http://www.goldcopd.com.
2. Restrepo R.D. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007, 52(7):833-851.
3. Barnes P.J. The pharmacological properties of tiotropium. Chest 2000, 117(2 Suppl.):63S-66S.
4. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
5. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26(2):214-222.
6. Di Marco F., Verga M., Santus P., Morelli N., Cazzola M., Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006, 100(11):1925-1932.
7. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129(3):509-517.
8. Hanania N.A., Boota A., Kerwin E., Tomlinson L., Denis-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs 2009, 69(9):1205-1216. 18.
9. Vogelmeier C., Kardos P., Harari S., Gans S.J., Stenglein S., Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008, 102(11):1511-1520.
10. Tashkin D.P., Hanania N.A., McGinty J., Denis-Mize K., Chaudry I. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther 2009, 26(11):1024-1034.
11. Tashkin D.P., Varghese S. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharmacol Ther 2011, 24(1):147-152.
12. Cazzola M., Noschese P., Salzillo A., De Giglio C., D'Amato G., Matera M.G. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005, 99(5):524-528.
13. Tashkin D.P., Littner M., Andrews C.P., Tomlinson L., Rinehart M., Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008, 102(4):479-487.
14. Tashkin D., Varghese S. Formoterol treatment plus Tiotropium results in greater improvements in lung function compared with Tiotropium administered alone in patients with COPD. J Allergy Clin Immunol 2007, 119(1):S4.
15. Cazzola M., Tashkin D.P. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009, 6(5):404-415.
16. Cazzola M., Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23(4):257-267.
17. Cazzola M., Matera M.G. The effective treatment of COPD: anticholinergics and what elseα. Drug Discov Today Ther Strateg 2006, 3:277.
18. Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient centred outcomes. Prim Care Respir J 2012, 21(1):101-108.
19. Rhoden K.J., Meldrum L.A., Barnes P.J. Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors. J Appl Physiol 1998, 65:700-705.
20. Duranti R., Filippelli M., Bianchi R., Romagnoli I., Pellegrino R., Brusasco V., et al. Inspiratory Capacity and decrease in lung hyperinflation with Albuterol in COPD. Chest 2002, 122:2009-2014.
21. O'Donnell D.E., Webb K.A. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis 1993, 148:1351-1357.
22. Newton M.F., O'Donnell D.E., Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002, 121:1042-1050.
23. Postma D.S., Keyzer J.J., Koeter G.H., Sluiter H.J., De Vries K. Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin Sci 1985, 69:251-258.
24. Brashier B., Dhembare P., Jantikar A., Mahadik P., Gokhale P., Gogtay J.A., et al. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD. Respir Med 2007, 101(12):2464-2471.
25. Cazzola M., Di Marco F., Santus P., Boveri B., Verga M., Matera M.G., et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004, 17:35-39.